Johnson and Johnson (JNJ) - News Archive

Johnson & Johnson s recent announcement of its intent to separate its Orthopaedics business signifies a strategic maneuver aimed at enhancing operational focus and driving stakeholder value. This article discusses the i...

In the ever-fluctuating financial realm, Wednesday, July 16, 2025, emerges as a promising day at CSIMarket.com, with a cautiously positive trajectory across stock markets. Key players are driving mar...

Johnson & Johnson s Strategic Investment Surge: A Catalyst for Growth in the Pharmaceutical Sector In a significant development that underscores the ongoing evolution of the pharmaceutical industry, Johnson & Johnson (J...

In a bold move that reflects its commitment to innovation and growth, Johnson & Johnson (NYSE: JNJ) announced a significant expansion of its investment footprint in the United States. Over the next four years, the healt...

In a strategic move designed to bolster its cardiovascular portfolio, Johnson & Johnson (NYSE: JNJ) has announced its definitive agreement to acquire V-Wave Ltd., a private biotechnology company that is pioneering innov...

In the world of business, staying ahead of the competition is essential to success. Johnson And Johnson, a renowned multinational conglomerate, seems to have mastered this art, as evidenced by its recent exceptional per...

Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2024 Amidst Declining Stock PerformanceIn the recent press release from Johnson & Johnson, the company has declared a cash dividend for the third quarter...

Johnson & Johnson Strengthens Pipeline with Acquisition of Yellow Jersey Therapeutics, Gaining Ownership of NM26Johnson & Johnson, a leading pharmaceutical company, has announced the successful completion of its acquisi...

Johnson & Johnson, a leading healthcare company, has recently completed its acquisition of Shockwave Medical, further reinforcing its presence in the global medical technology market. Shockwave Medical will now operate...

Johnson & Johnson Acquires Numab Subsidiary for $1.25 Billion Amid Revenue Declines but Improved Profit Margins NEW BRUNSWICK, N.J. In a strategic move to strengthen its portfolio in immunology and expand its presence i...

Johnson & Johnson (J&J), a multinational pharmaceutical and personal care product company, has revealed a resolution strategy designed to address all current and future ovarian cancer claims arising from litigation rela...

In a significant move to strengthen its position in the biopharmaceutical market, Johnson & Johnson (J&J) recently completed the acquisition of Ambrx Biopharma, Inc., a clinical-stage biopharmaceutical company specializ...

Johnson & Johnson, a leading multinational pharmaceutical and medical devices company, recently held an Enterprise Business Review to discuss its strategic plans for long-term competitive growth. The event, which took p...

Johnson & Johnson Appoints Eugene A. Woods as New Board Member Amidst Declining Stock PerformanceJohnson & Johnson, a leading healthcare company, has announced the appointment of Eugene A. Woods, MBA, MHA, Chief Executi...

In a recent development in the legal battle against Johnson & Johnson (NYSE: JNJ), the settlements of two talcum powder trials in California have dealt a significant blow to the company s claim that bankruptcy is its on...

Johnson & Johnson (NYSE: JNJ) recently announced that its Board of Directors has approved a cash dividend of $1.19 per share for the fourth quarter of 2023. This dividend will be paid out on December 5, 2023, to shareho...

NEW BRUNSWICK, N.J. - Johnson & Johnson, a leading healthcare company, unveiled its robust results for the third quarter of 2023. The company s CEO, Joaquin Duato, praised the strong performance and significant advancem...